Stem cell research for Type 1 

The US FDA has granted Fast Track Designation for VX-880, an investigational allogeneic human stem cell-derived islet cell therapy for people with Type 1 diabetes.

VX-880, formerly known as STx-02, is being evaluated for patients who have T1D with impaired hypoglycaemic awareness and severe hypoglycaemia in a clinical trial by Vertex Pharmaceuticals Incorporated.

VX-880 could restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including insulin production. The trial will involve an infusion of fully differentiated, functional islet cells and the chronic administration of concomitant immunosuppressive therapy to protect the islet cells from immune rejection.

“It’s a remarkable time for Type 1 diabetes research efforts worldwide, as this investigational treatment enters the clinic,” said Camillo Ricordi, M.D., Professor of Surgery, Director of the Diabetes Research Institute (DRI) and the Cell Transplant Center at the University of Miami Miller School of Medicine, and Steering Committee Chair for the VX-880 clinical trial.

“The field’s experience with the limited cadaveric islet transplants available, where some patients have experienced prolonged insulin independence for years, provides important proof-of-concept for the potential of cell therapy to be transformative for patients living with Type 1 diabetes.”

 

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags